Embed Size (px)
Citation preview
Female Condom Consortium
Presentation byYvonne Bogaarts
World Population Foundation
25 October 2007
Reproductive Health Supplies CoalitionSEMI-ANNUAL MEMBERSHIP MEETING
Structure
– State of the Art– Acceptibility– Obstacles– Potential of female condom– Consortium: partners & plans
• R&D• Implementation in selected countries• Knowledge centre
– Difference the RHSC can make
Female condom products
• Female Health Company in USA: FC 1 (poly-urethane) (approved by USFDA, 1993)
• FC 2 (nitrile) (approved by WHO 2006)
Medtech Health Products in India: V’Amour FC/Dr. Reddy (latex) (approved by India Drug Controller in 2003, not approved by WHO)
Forthcoming
PATH: development of a better product
Timing: will take another 2-3 years
Female Health Company
• US based company • Introduction 1992, approved USFDA in 1993• Production started in 1996• In 2007: sole manufacturer for donor and UN
agencies • Production increased 10x times since 1996• Production in 2005: 22 million female condoms
(12 million for developing countries)• Available in 108 countries
Buyers of the female condom
In 2004• 2,3 million by UNFPA • 2 million bought by USAID• 1,6 million by DFID• Rest donors: KfW and DANIDA• Governments of Brazil, South Africa, Zimbabwe,
France, Kenya• Private sector/NGO: PSI, DKT, IPPF and MSI• Private sector/ shops(P. Friel, 2005)
Global consultations
• 1993 “Potential Role of the Female Condom in International AIDS Prevention”, AIDSCAP
• 1997 “The Female Condom: From Research to Marketplace” AIDSCAP
• 2001 “Technical Update on the Female Condom” FHI
• 2004 Expert meeting on female condom GCM/GCWA
• 2005 Global Consultation on Female Condoms (Baltimore)
Same barriers discussed
- stereotypes on women and sexuality
- pre-conceived ideas
- costs
- lack of funding and funders
- provider resistance
Acceptibility
• No static fact
• Studies indicate high acceptability rate
• Acceptability influenced by: - individual factors – insertion skills and practice- male partners- environment
Potential of female condom
Female Condom is:
+ effective contraceptive
+ protects against STIs, including HIV
+ women-initiated
+ available NOW
=
a real addition to method mix
Potential of female condom
Female condom important in context of:
• high maternal mortality rate
• feminisation of HIV/AIDS
• limited choice infection-prevention methods
• high cost and limited availability AIDS treatment
Female Condom Consortium:Tackle the Challenges
Five partners:
- Oxfam Novib
- World Population Foundation
- Dutch Ministry of Foreign Affairs
- JIPPY Foundation
- IDA Solutions
Plans Female Condom Consortium
R&D: cheaper female condom
Country programme
Knowledge centre
Research & Development
• Female Condom Consortium: development of cheaper product
• Latex
Timing• FCC: May 2008 to be on the market
Quality assurance: international (WHO)
Country programme
• Nigeria: 3 selected states• Malawi
National Advisory Board set up
Main actors:• Civil society: IEC, distribution• Government and UN: advocacy, support IEC and
distribution, financing• Private sector: subsidised distribution and promotion,
sale at affordable price
Country programme
Main areas:
- Registration: national (NAFDAC)
- Procurement, Logistics, Importation, Distribution
- Marketing and Sales
- Monitoring & Evaluation
Knowledge centre
• Data base• Disseminate results country implementation• Advocacy• Enhance collaboration and cooperation
Working for professionals in the field, donor community and policymakers
What difference RHSC make?
• Positive Advocacy for the female condom,
not ridicule it!
• Support ongoing and further R&D
• Funding
